Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Text Size
8 studies found for:    "Subcutaneous panniculitis-like T-cell lymphoma"

Modify this search | How to Use Search Results

Show Display Options
RSS Create an RSS feed from your search for:
"Subcutaneous panniculitis-like T-cell lymphoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
Conditions: T-Cell Peripheral Lymphoma;   Gamma Delta Hepatosplenic T-Cell Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   NK T-Cell Lymphoma
Interventions: Biological: Rituximab;   Drug: EPOCH;   Biological: Siplizumab
2 Recruiting CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Conditions: Peripheral T-Cell Lymphoma;   Angioimmunoblastic T Cell Lymphoma;   ALK-negative Anaplastic Large Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma;   Acute Adult T-Cell Leukemia/Lymphoma
Interventions: Drug: CEOP/IVE/GDP chemotherapy regimen;   Drug: CEOP chemotherapy regimen for 6 cycles
3 Recruiting CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Conditions: ALK-negative Anaplastic Large Cell Lymphoma;   Peripherial T Cell Lymphoma,Not Otherwise Specified;   Angioimmunoblastic T Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Hepatosplenic T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma
Interventions: Drug: Cyclophosphamide 750mg/m2;   Drug: Vincristine 1.4mg/m2;   Drug: Doxorubicin 50mg/m2;   Drug: prednisone 60mg/m2;   Drug: ifosfamide 2000mg/m2;   Drug: pirarubicin 50mg/m2;   Drug: pirarubicin 25mg/m2;   Drug: Etoposide phosphate 100mg/m2;   Drug: methotrexate 1500mg/m2
4 Recruiting Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   B Lymphoblastic Leukemia/Lymphoma;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Burkitt Leukemia;   Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Mycosis Fungoides;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Nodal Marginal Zone Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Post-Transplant Lymphoproliferative Disorder;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Primary Effusion Lymphoma;   Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   Systemic Anaplastic Large Cell Lymphoma;   T Lymphoblastic Leukemia/Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Dietary Supplement: Salvia hispanica Seed
5 Recruiting Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Conditions: Aggressive Non-Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Refractory Anaplastic Large Cell Lymphoma;   Small Lymphocytic Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions: Dietary Supplement: Cholecalciferol;   Other: Laboratory Biomarker Analysis
6 Terminated Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Conditions: 714leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Everolimus
7 Terminated
Has Results 		Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Vorinostat;   Drug: Bortezomib
8 Completed
Has Results 		SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Drug: Zolinza (vorinostat);   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
To Top

† Study has passed its completion date and status has not been verified in more than two years.